Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Long-Term Deferred Tax (2020 - 2025)

Cytek Biosciences filings provide 6 years of Long-Term Deferred Tax readings, the most recent being $38.4 million for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax rose 24.74% to $38.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $38.4 million, a 24.74% increase, with the full-year FY2024 number at $33.4 million, up 9.47% from a year prior.
  • Long-Term Deferred Tax hit $38.4 million in Q3 2025 for Cytek Biosciences, up from $35.8 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $38.4 million in Q3 2025 to a low of $7.4 million in Q2 2021.
  • Median Long-Term Deferred Tax over the past 5 years was $25.2 million (2023), compared with a mean of $23.3 million.
  • Biggest five-year swings in Long-Term Deferred Tax: skyrocketed 125.74% in 2023 and later grew 3.06% in 2025.
  • Cytek Biosciences' Long-Term Deferred Tax stood at $9.2 million in 2021, then soared by 123.03% to $20.5 million in 2022, then surged by 49.02% to $30.5 million in 2023, then increased by 9.47% to $33.4 million in 2024, then grew by 15.04% to $38.4 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $38.4 million (Q3 2025), $35.8 million (Q2 2025), and $33.7 million (Q1 2025) per Business Quant data.